Decoding The Surge: Palisade Bio (PALI) Shares On The Move
Decoding The Surge: Palisade Bio (PALI) Shares On The Move
The current trading session has witnessed a notable surge in the shares of Palisade Bio, Inc. (NASDAQ: PALI), with an impressive increase of 21.46%, elevating its value to $7.32. This substantial uptick in PALI stock price follows the successful completion of an analysis for the development of a new drug.
在本交易日中，Palisade Bio, Inc.（纳斯达克股票代码：PALI）的股价显著上涨，上涨了21.46％，使其价值升至7.32美元。PALI股价的大幅上涨是在成功完成新药开发分析之后出现的。
Today, Palisade Bio (PALI) has announced the successful conclusion of its analysis assessing the impact of bioactivated PALI-2108 on TNF-α production in a whole blood (WB) assay. PALI-2108, an orally administered, locally acting, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug developed by Palisade, targets patients afflicted with UC.
今天，Palisade Bio（PALI）宣布其分析成功结束，该分析评估了生物活化的 PALI-2108 对全血（WB）检测中肿瘤坏死因子α生成的影响。PALI-2108 是Palisade开发的一种口服、局部作用、结肠特异性磷酸二酯酶4（PDE4）抑制剂前药，靶向UC患者。
The obtained data fortifies Palisade Bio's confidence in the robust anti-inflammatory capabilities of PALI-2108 in managing UC. The superior efficacy of PALI-2108, evidenced by its lower half-maximal inhibitory concentration (IC50) compared to the approved PDE4 inhibitor apremilast, underscores its potential as an advanced therapeutic option for inflammatory bowel disease patients.
获得的数据增强了 Palisade Bio 对 PALI-2108 在管理 UC 方面的强大抗炎能力的信心。与批准的PDE4抑制剂apremilast相比，其较低的半最大抑制浓度（IC50）证明了PALI-2108 的卓越疗效，这凸显了其作为炎症性肠病患者先进治疗选择的潜力。
This comprehensive study involved WB samples from 14 clinically healthy adults, comprising five women and nine men. Twelve samples meeting the inclusion criteria were utilized for TNF-α measurement and IC50 value calculation. Donor whole blood underwent treatment with varied concentrations of PALI-2108 and two control compounds known for inhibiting the PDE4 pro-inflammatory pathway, subsequently being challenged with the pro-inflammatory molecule lipopolysaccharide (LPS).
这项全面的研究涉及来自14名临床健康的成年人的WB样本，包括5名女性和9名男性。使用了十二个符合纳入标准的样本进行肿瘤坏死因子α测量和IC50值计算。捐赠者的全血接受了不同浓度的 PALI-2108 和两种已知可抑制 PDE4 促炎途径的对照化合物的治疗，随后受到了促炎分子脂多糖（LPS）的挑战。
Anti-inflammatory potency was determined by computing IC50 values for TNF-α inhibition. Results from the study showcased the efficacy of PALI-2108 in inhibiting LPS-induced TNF-α production in this ex-vivo peripheral whole blood assay. Pretreatment of human whole blood samples with bioactivated PALI-2108 led to a significant reduction in LPS-induced TNF-α production compared to non-pretreated samples.
抗炎效力是通过计算肿瘤坏死因子α抑制的IC50值来确定的。该研究的结果表明，在这项体外周全血分析中，PALI-2108 在抑制 LPS 诱导的肿瘤坏死因子-α产生方面的功效。与未经预处理的样本相比，使用生物活化的 PALI-2108 对人体全血样本进行预处理可显著减少 LPS 诱导的肿瘤坏死因子α的产生。
The study was conducted in collaboration with Paraza Pharma, Inc., headquartered in Montreal, QC. Palisade Bio's exceptional operational performance is propelling the clinical advancement of PALI-2108 towards its first-in-human study, slated to commence later this year. Palisade Bio remains dedicated to advancing its innovative research endeavors aimed at enhancing the quality of life for UC patients and those affected by other inflammatory conditions.
该研究是与总部位于魁北克蒙特利尔的Paraza Pharma, Inc.合作进行的。Palisade Bio的卓越运营业绩正在推动 PALI-2108 的临床进展，迈向其首次人体研究，该研究定于今年晚些时候开始。Palisade Bio仍然致力于推进其创新研究工作，旨在提高UC患者和其他炎症性疾病患者的生活质量。